How do you utilize ibrutinib + R-CHOP in the frontline treatment of DLBCL?  

Would you consider the combination in patients <60 years old with non-GCB subtype disease, based on the PHOENIX trial subset analysis? (Younes et al. J Clin Oncol 2019. doi: 10.1200/JCO.18.02403.)